Physician profile
Matthew David Olin
NPI 1962496547
$23,644.81
in general payments reported to CMS, 2019-2025
9 companies · $3,267 in 2025
The $3,267 reported for 2025 was more than what 78% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,910 · 2020: $120 · 2021: $1,399 · 2022: $1,941 · 2023: $5,989 · 2024: $5,018 · 2025: $3,267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $14K · Food and Beverage: $399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $13,875.22 |
| Food and Beverage | $399.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Encore Medical, LP | $13,970.23 | 2019-2025 | Djo Surgical |
| Medical Device Business Services, INC. | $6,680.78 | 2019-2022 | |
| Southtech Orthopedics | $1,200.00 | 2021 | |
| Zimmer Biomet Holdings, INC. | $1,111.89 | 2019-2024 | Affixus, Tapestry, Rosa |
| Depuy Synthes Sales INC. | $402.22 | 2019-2025 | Attune |
| Arthrex, INC. | $122.46 | 2021 | |
| Stryker Corporation | $93.65 | 2023 | |
| Smith+Nephew, INC. | $35.91 | 2022 | |
| Botanix Sb INC | $27.67 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Olin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.